Candel Therapeutics Inc

Market Cap

$596M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.51+$3.07 (+56.43%)

Jun 5, 2026

52W High $9.2752W Low $4.42

Company Details

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical tria...

CEO

—

IPO Date

Jul 27, 2021

Website

www.candeltx.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$54M

EPS (Diluted)

Free Cash Flow

-$49M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 14, 2026

FY 2025

Mar 12, 2026

Q4 2025

Mar 12, 2026

$0-100.0%

Q3 2025

Nov 13, 2025

Q2 2025

Aug 14, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee